Obulytix
Obulytix leverages proprietary phage lysin-based antibiotics technology to combat antibiotic-resistant bacteria, offering specificity, absence of resistance development, and the capability to eradicate chronic infections using nature.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
* | €4.0m | Early VC | |
| Total Funding | 000k | ||
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads